[{"text": "In particular , H1975 cells contain a second mutation ( T790M ) reported to be linked to gefitinib resistance , but we found that these cells also responded poorly to cetuximab .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [89, 98], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [56, 61], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [56, 61], "obj_char_span": [89, 98], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Therefore , in this study we explored the retained antitumor activity of gefitinib in resistant HCC827-GR5 and NCI-H1975 NSCLC cells , carrying MET amplification and T790M mutation , respectively .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [73, 82], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [166, 171], "tok_span": [38, 42]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [166, 171], "obj_char_span": [73, 82], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 42], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "The most commonly identified mechanism of resistance is an EGFR mutation at position 790 ( T790M ) , resulting in substitution of a threonine residue with methionine , which abrogates the ability of gefitinib or erlotinib to inhibit EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [199, 208], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [91, 96], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [91, 96], "obj_char_span": [199, 208], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "As to H1975 with L858R + T790M , gefitinib significantly improved NK cells cytotxicity ( Figure", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [33, 42], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [25, 30], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [17, 22], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [25, 30], "obj_char_span": [33, 42], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [16, 20]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [17, 22], "obj_char_span": [33, 42], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Stat3 is a key factor in gefitinib-resistant EGFR T790M cells .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [25, 44], "tok_span": [7, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [50, 55], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [50, 55], "obj_char_span": [25, 44], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [7, 13]}], "umls_entity_list": []}, {"text": "Gatekeeper mutations , the T790M mutation in EGFR associated with resistance to gefitinib , are common mechanisms by which tumor cells acquire resistance to molecularly targeted drugs .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [80, 89], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [27, 32], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [27, 32], "obj_char_span": [80, 89], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Although irreversible EGFR-TKIs , including BIBW2992 , have been developed to overcome T790M mediated resistance to gefitinib , recent clinical trials have failed to show that monotherapy with irreversible EGFR-TKIs has benefits in patients with NSCLC refractory to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [116, 125], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [87, 92], "tok_span": [18, 22]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [266, 275], "tok_span": [53, 57]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [87, 92], "obj_char_span": [116, 125], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [25, 29]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [87, 92], "obj_char_span": [266, 275], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [53, 57]}], "umls_entity_list": []}, {"text": "In our study , carcinoma of esophagogastric junction rarely presents EGFR mutations , especially gefitinib associated mutations such as L858R and delE746-A750 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [97, 106], "tok_span": [16, 20]}, {"name": "L858R", "ent_type": "variant", "char_span": [136, 141], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [136, 141], "obj_char_span": [97, 106], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Adenocarcinoma of esophagogastric junction rarely presents EGFR mutation , especially gefitinib associated mutations such as L858R , or delE746-A750 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [86, 95], "tok_span": [13, 17]}, {"name": "L858R", "ent_type": "variant", "char_span": [125, 130], "tok_span": [21, 25]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [125, 130], "obj_char_span": [86, 95], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "The human lung adenocarcinoma cell lines , A549 ( EGFR wild type ) , H1975 ( EGFR L858R/T790M , gefitinib-resistant ) , H1299 ( EGFR wild type , p53 null ) , and H3255 ( EGFR L858R ) were purchased from American Type Culture Collection ( ATCC ; Manassas , VA , USA ) .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [96, 115], "tok_span": [30, 36]}, {"name": "L858R", "ent_type": "variant", "char_span": [175, 180], "tok_span": [57, 61]}], "relation_list": [{"subject": "L858R", "object": "gefitinib-resistant", "sbj_char_span": [175, 180], "obj_char_span": [96, 115], "rel_type": "sensitivity", "sbj_tok_span": [57, 61], "obj_tok_span": [30, 36]}], "umls_entity_list": []}, {"text": "In conclusion , the current study reports a rare case of lung cancer harboring an L858R point mutation of exon 21 and a compound T790M EGFR substitution mutation following treatment with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [187, 196], "tok_span": [37, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [129, 134], "tok_span": [27, 31]}, {"name": "L858R", "ent_type": "variant", "char_span": [82, 87], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [129, 134], "obj_char_span": [187, 196], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [37, 41]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [82, 87], "obj_char_span": [187, 196], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Gefitinib sensitizing EGFR mutations , such as L858R and exon 19 in-frame deletions , selectively activate antiapoptosis signaling pathways .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [47, 52], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [47, 52], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) , including exon 19 deletions and the exon 21 L858R point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [223, 232], "tok_span": [44, 48]}, {"name": "L858R", "ent_type": "variant", "char_span": [128, 133], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [128, 133], "obj_char_span": [223, 232], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "Importantly , the wild type protein formed fibrils only at 10 μM erlotinib , whereas the TKI-sensitive mutants relocated to fibrils in the presence of 10–100 nM erlotinib , and this effect was fully abrogated by the erlotinib-resistant T790M mutation .", "entity_list": [{"name": "μM erlotinib", "ent_type": "drug", "char_span": [62, 74], "tok_span": [11, 17]}, {"name": "erlotinib-resistant T790M", "ent_type": "variant", "char_span": [216, 241], "tok_span": [53, 63]}, {"name": "nM erlotinib", "ent_type": "drug", "char_span": [158, 170], "tok_span": [37, 42]}, {"name": "the erlotinib-resistant", "ent_type": "drug", "char_span": [212, 235], "tok_span": [52, 59]}], "relation_list": [{"subject": "erlotinib-resistant T790M", "object": "μM erlotinib", "sbj_char_span": [216, 241], "obj_char_span": [62, 74], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 63], "obj_tok_span": [11, 17]}, {"subject": "erlotinib-resistant T790M", "object": "nM erlotinib", "sbj_char_span": [216, 241], "obj_char_span": [158, 170], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 63], "obj_tok_span": [37, 42]}, {"subject": "erlotinib-resistant T790M", "object": "the erlotinib-resistant", "sbj_char_span": [216, 241], "obj_char_span": [212, 235], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 63], "obj_tok_span": [52, 59]}], "umls_entity_list": []}, {"text": "This compound was previously found to be active against EGFR containing the exon 20 point mutation T790M , associated with resistance to gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [151, 160], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [99, 104], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [99, 104], "obj_char_span": [151, 160], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "In pretreated patients harboring a T790M mutation , low expression of BRCA1 mRNA is correlated with a prolonged progression-free survival to erlotinib treatment .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [141, 150], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [35, 40], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [35, 40], "obj_char_span": [141, 150], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Second-generation irreversible EGFR inhibitors , which bind irreversibly in the ATP binding pocket of EGFR through a covalent bond at C797 , were shown to be more potent inhibitors of the second-site T790M mutation than erlotinib or gefitinib in pre-clinical models ( ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [220, 229], "tok_span": [45, 49]}, {"name": "T790M", "ent_type": "variant", "char_span": [200, 205], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [200, 205], "obj_char_span": [220, 229], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "Presence of T790M substitution may be an indication for treatment with irreversible EGFR TKI , such as neratinib , keratinib and especially afatinib , which is currently in the third phase of clinical trials . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [12, 17], "tok_span": [2, 6]}, {"name": "afatinib", "ent_type": "drug", "char_span": [140, 148], "tok_span": [30, 32]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [12, 17], "obj_char_span": [140, 148], "rel_type": "response", "sbj_tok_span": [2, 6], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Second-generation TKIs that irreversibly inhibit the EGFR TKI domain may offer the potential for overcoming the resistance of T790M mutation to erlotinib and gefitinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [144, 153], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [126, 131], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [126, 131], "obj_char_span": [144, 153], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "It is well known that the efficacy of targeted therapies such as gefitinib or erlotinib with NSCLC patients depends on the presence of EGFR activating mutations including in-frame deletion in exon 19 or L858R in exon 21 . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [78, 87], "tok_span": [17, 21]}, {"name": "L858R", "ent_type": "variant", "char_span": [203, 208], "tok_span": [41, 45]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [203, 208], "obj_char_span": [78, 87], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Moreover , interactions between Erlotinib and MYO2 or MYH9 have been described , and a MYH9 inhibitor synergizes with EGFR inhibitors to induce apoptosis in cells carrying the drug-resistant mutation T790M .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [32, 41], "tok_span": [4, 7]}, {"name": "T790M", "ent_type": "variant", "char_span": [200, 205], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [200, 205], "obj_char_span": [32, 41], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 45], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "Kim and colleagues demonstrated that the combination of lapatinib with cetuximab overcame gefitinib resistance due to the secondary T790M mutation in NSCLC by inducing enhanced cytotoxicity both in vitro and in vivo .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [71, 80], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [132, 137], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [132, 137], "obj_char_span": [71, 80], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Furthermore , the association of cetuximab with afatinib has been shown to be effective to overcome T790M mediated drug resistance .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [33, 42], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [100, 105], "tok_span": [20, 24]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [100, 105], "obj_char_span": [33, 42], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "( A ) Cetuximab suppresses the growth of Ba/F3 cells dependent upon the G719S and G724S mutants , but not control cells .", "entity_list": [{"name": "Cetuximab", "ent_type": "drug", "char_span": [6, 15], "tok_span": [3, 6]}, {"name": "G719S", "ent_type": "variant", "char_span": [72, 77], "tok_span": [18, 22]}, {"name": "G724S", "ent_type": "variant", "char_span": [82, 87], "tok_span": [23, 27]}], "relation_list": [{"subject": "G719S", "object": "Cetuximab", "sbj_char_span": [72, 77], "obj_char_span": [6, 15], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [3, 6]}, {"subject": "G724S", "object": "Cetuximab", "sbj_char_span": [82, 87], "obj_char_span": [6, 15], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Materials and Methods 49 individual specimens of 21 metastatic CRCs and corresponding metastases collected before and after combined therapy with cetuximab were examined using CGH , certified PCR/DNA sequencing protocols ( KRAS exon 2 , Gl12/13 ; BRAF exon 15 , V600E ) as well as allele-specific PCR .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [146, 155], "tok_span": [21, 25]}, {"name": "V600E", "ent_type": "variant", "char_span": [262, 267], "tok_span": [52, 55]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [262, 267], "obj_char_span": [146, 155], "rel_type": "resistance or non-response", "sbj_tok_span": [52, 55], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "Others stabilise the active conformation of the receptor , which also prevents imatinib binding ( D820Y and N822K ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [79, 87], "tok_span": [13, 15]}, {"name": "D820Y", "ent_type": "variant", "char_span": [98, 103], "tok_span": [17, 21]}], "relation_list": [{"subject": "D820Y", "object": "imatinib", "sbj_char_span": [98, 103], "obj_char_span": [79, 87], "rel_type": "response", "sbj_tok_span": [17, 21], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "GIST-T1R cells were generated by chronic , intermittent culture with imatinib , which resulted in the acquisition of an exon 13 mutation at KIT V654A .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [69, 77], "tok_span": [15, 17]}, {"name": "V654A", "ent_type": "variant", "char_span": [144, 149], "tok_span": [31, 35]}], "relation_list": [{"subject": "V654A", "object": "imatinib", "sbj_char_span": [144, 149], "obj_char_span": [69, 77], "rel_type": "resistance", "sbj_tok_span": [31, 35], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Two of these mutations were located in the kinase domain and are known to mediate resistance to lapatinib ( L755S ) or to activate Her2 ( D769H ) .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [96, 105], "tok_span": [17, 20]}, {"name": "L755S", "ent_type": "variant", "char_span": [108, 113], "tok_span": [21, 25]}, {"name": "D769H", "ent_type": "variant", "char_span": [138, 143], "tok_span": [32, 36]}], "relation_list": [{"subject": "L755S", "object": "lapatinib", "sbj_char_span": [108, 113], "obj_char_span": [96, 105], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [17, 20]}, {"subject": "D769H", "object": "lapatinib", "sbj_char_span": [138, 143], "obj_char_span": [96, 105], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "T790M mutation occurs by substitution of the amino acid threonine by methionine in amino acid position 790 ( T790M ) on exon 20 and is similar to the KIT T670I gatekeeper mutation observed in imatinib-resistant gastrointestinal stromal tumor .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [192, 210], "tok_span": [48, 52]}, {"name": "T670I", "ent_type": "variant", "char_span": [154, 159], "tok_span": [38, 42]}], "relation_list": [{"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [154, 159], "obj_char_span": [192, 210], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "In contrast to crizotinib , alectinib also shows substantial inhibitory activity against the L1196M mutant of ALK , apparently because it is able to maintain an efficient ( CH/π ) interaction with position 1196 even after the substitution of methionine for leucine .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [15, 25], "tok_span": [3, 7]}, {"name": "L1196M", "ent_type": "variant", "char_span": [93, 99], "tok_span": [18, 22]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [93, 99], "obj_char_span": [15, 25], "rel_type": "resistance", "sbj_tok_span": [18, 22], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Studies of ALK rearranged lung cancers with acquired resistance to crizotinib have identified ALK fusion gene amplification and secondary ALK TK domain mutations ( L1196M and G1269A ) in about one third of cases .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [67, 77], "tok_span": [12, 16]}, {"name": "L1196M", "ent_type": "variant", "char_span": [164, 170], "tok_span": [31, 35]}, {"name": "G1269A", "ent_type": "variant", "char_span": [175, 181], "tok_span": [36, 40]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [164, 170], "obj_char_span": [67, 77], "rel_type": "resistance", "sbj_tok_span": [31, 35], "obj_tok_span": [12, 16]}, {"subject": "G1269A", "object": "crizotinib", "sbj_char_span": [175, 181], "obj_char_span": [67, 77], "rel_type": "resistance", "sbj_tok_span": [36, 40], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Moreover , afatinib is able to inhibit the kinase activity in vitro and in animal models when a resistant T790M mutation is concomitant to a sensitivity mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [11, 19], "tok_span": [2, 4]}, {"name": "T790M", "ent_type": "variant", "char_span": [106, 111], "tok_span": [20, 24]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [106, 111], "obj_char_span": [11, 19], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR T790M models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .", "entity_list": [{"name": ", afatinib", "ent_type": "drug", "char_span": [48, 58], "tok_span": [13, 16]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [141, 151], "tok_span": [38, 43]}], "relation_list": [{"subject": "EGFR T790M", "object": ", afatinib", "sbj_char_span": [141, 151], "obj_char_span": [48, 58], "rel_type": "response", "sbj_tok_span": [38, 43], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "It has been reported that ponatinib has potent activity against T315I mutant cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [26, 35], "tok_span": [5, 9]}, {"name": "T315I", "ent_type": "variant", "char_span": [64, 69], "tok_span": [13, 17]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [64, 69], "obj_char_span": [26, 35], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Thus , we examined ponatinib activity by using Ba/F3 BCR-ABL T315I mutant cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [19, 28], "tok_span": [4, 8]}, {"name": "T315I", "ent_type": "variant", "char_span": [61, 66], "tok_span": [19, 23]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [61, 66], "obj_char_span": [19, 28], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "( D ) Ba/F3 T315I cells were treated with ponatinib for 24 h , and total extracts were examined by immunoblot analysis with anti-phospho ABL , anti-Crk-L , anti cleaved caspase 3 , anti-PARP , and anti-tubulin antibodies .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [42, 51], "tok_span": [15, 19]}, {"name": "T315I", "ent_type": "variant", "char_span": [12, 17], "tok_span": [7, 11]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [12, 17], "obj_char_span": [42, 51], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Several strategies targeting T315I BCR-ABL including blockade of kinase-addiction by the third-generation of tyrosine kinase inhibitor ponatinib , down-modulation of BCR-ABL by inhibition of heat shock protein were documented .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [135, 144], "tok_span": [26, 30]}, {"name": "T315I", "ent_type": "variant", "char_span": [29, 34], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [29, 34], "obj_char_span": [135, 144], "rel_type": "response", "sbj_tok_span": [3, 7], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "The L858R substitution ( an arginine for leucine substitution at amino acid 858 ) is one of the most frequently reported mutations and shows good responses to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [159, 168], "tok_span": [31, 35]}, {"name": "L858R", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [159, 168], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "These T790M mutation seemed to be the cause of gefitinib resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [6, 11], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [6, 11], "obj_char_span": [47, 56], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Contrarily , a point mutation in the EGFR gene , which results in the substitution of methionine for threonine at position 790 ( T790M ) , decreases the ability of erlotinib or gefitinib to inhibit EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [41, 45]}, {"name": "T790M", "ent_type": "variant", "char_span": [129, 134], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [129, 134], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [41, 45]}], "umls_entity_list": []}, {"text": "Patients with exon 19 harboring deletions were found to have longer survival following treatment with gefitinib or erlotinib compared with those having L858R mutations in NSCLC ; however , Marks et al. reported no difference in survival between exon 19 deletions and L858R mutations in the absence of EGFR targeted therapy .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [102, 111], "tok_span": [15, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [152, 157], "tok_span": [28, 32]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [152, 157], "obj_char_span": [102, 111], "rel_type": "sensitivity", "sbj_tok_span": [28, 32], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "The possibility of detection of T790M mutation in EGFR-TKIs naive patients forces to expand the diagnostics of EGFR gene status during qualification for erlotinib or gefitinib treatment and to consider the new therapy modalities in carriers of this mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [166, 175], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [32, 37], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [32, 37], "obj_char_span": [166, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "However , patients with wild-type EGFR and acquired mutation in EGFR T790M are eventually resistant to treatment with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [118, 127], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [69, 74], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [69, 74], "obj_char_span": [118, 127], "rel_type": "resistance or non-response", "sbj_tok_span": [13, 17], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and EGFR mutant ( delE746-A750 , L858R ) NSCLC cells ( HCC827 ) and gefitinib-resistant and EGFR mutant ( T790M ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "entity_list": [{"name": "gefitinib-sensitive", "ent_type": "drug", "char_span": [100, 119], "tok_span": [22, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [226, 231], "tok_span": [64, 68]}, {"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [188, 207], "tok_span": [54, 60]}, {"name": "L858R", "ent_type": "variant", "char_span": [153, 158], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-sensitive", "sbj_char_span": [226, 231], "obj_char_span": [100, 119], "rel_type": "resistance or non-response", "sbj_tok_span": [64, 68], "obj_tok_span": [22, 28]}, {"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [226, 231], "obj_char_span": [188, 207], "rel_type": "resistance or non-response", "sbj_tok_span": [64, 68], "obj_tok_span": [54, 60]}, {"subject": "L858R", "object": "gefitinib-sensitive", "sbj_char_span": [153, 158], "obj_char_span": [100, 119], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [22, 28]}, {"subject": "L858R", "object": "gefitinib-resistant", "sbj_char_span": [153, 158], "obj_char_span": [188, 207], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [54, 60]}], "umls_entity_list": []}, {"text": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [197, 206], "tok_span": [48, 52]}, {"name": "T790M", "ent_type": "variant", "char_span": [109, 114], "tok_span": [27, 31]}, {"name": "L858R", "ent_type": "variant", "char_span": [38, 43], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [109, 114], "obj_char_span": [197, 206], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [48, 52]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [38, 43], "obj_char_span": [197, 206], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "Many of the patients that do relapse often harbor pre existing T790M EGFR mutation at very low levels within the original tumor population , leading to resistance after gefitinib treatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [169, 178], "tok_span": [31, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [63, 68], "tok_span": [11, 15]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [63, 68], "obj_char_span": [169, 178], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR T790M models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . ", "entity_list": [{"name": "preclinical gefitinib-", "ent_type": "drug", "char_span": [94, 116], "tok_span": [25, 31]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [141, 151], "tok_span": [38, 43]}], "relation_list": [{"subject": "EGFR T790M", "object": "preclinical gefitinib-", "sbj_char_span": [141, 151], "obj_char_span": [94, 116], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 43], "obj_tok_span": [25, 31]}], "umls_entity_list": []}, {"text": "In our case , a biopsy ( ‘re-biopsy’ ) revealed the T790M mutation in the EGFR gene , which was widely known as a second mutation resistant to EGFR TKIs , such as gefitinib and erlotinib .", "entity_list": [{"name": "as gefitinib", "ent_type": "drug", "char_span": [160, 172], "tok_span": [40, 45]}, {"name": "the T790M", "ent_type": "variant", "char_span": [48, 57], "tok_span": [14, 19]}], "relation_list": [{"subject": "the T790M", "object": "as gefitinib", "sbj_char_span": [48, 57], "obj_char_span": [160, 172], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 19], "obj_tok_span": [40, 45]}], "umls_entity_list": []}, {"text": "In Vivo Correlation of BIM/Bim Expression and Mutant EGFR Activity ( A and B ) Lung tumor bearing mice that express a tetracycline-inducible L858R mutant ( EGFRL858R ) ( A ) or an exon 19 deletion mutant ( EGFRΔL747–S752 ) ( B ) were treated with a single dose of either vehicle control or 50 mg/kg erlotinib intraperitoneally .", "entity_list": [{"name": "mg/kg erlotinib", "ent_type": "drug", "char_span": [293, 308], "tok_span": [79, 86]}, {"name": "L858R", "ent_type": "variant", "char_span": [141, 146], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "mg/kg erlotinib", "sbj_char_span": [141, 146], "obj_char_span": [293, 308], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [79, 86]}], "umls_entity_list": []}, {"text": "In tumors from patients not treated with either gefitinib or erlotinib , the 2369 C→T mutation ( T790M ) appears to be extremely rare . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [61, 70], "tok_span": [13, 17]}, {"name": "( T790M", "ent_type": "variant", "char_span": [95, 102], "tok_span": [25, 30]}], "relation_list": [{"subject": "( T790M", "object": "erlotinib", "sbj_char_span": [95, 102], "obj_char_span": [61, 70], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 30], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Sequencing Chromatograms with the T790M EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or erlotinib . ( D ) Cell line H1975 contains both an exon 21 L858R mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [314, 326], "tok_span": [78, 83]}, {"name": "L858R", "ent_type": "variant", "char_span": [376, 381], "tok_span": [97, 101]}, {"name": "T790M", "ent_type": "variant", "char_span": [34, 39], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "or erlotinib", "sbj_char_span": [376, 381], "obj_char_span": [314, 326], "rel_type": "sensitivity", "sbj_tok_span": [97, 101], "obj_tok_span": [78, 83]}, {"subject": "T790M", "object": "or erlotinib", "sbj_char_span": [34, 39], "obj_char_span": [314, 326], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [78, 83]}], "umls_entity_list": []}, {"text": "This study revealed that the quinazoline rings of erlotinib and lapatinib interact differently with the EGFR kinase domain , suggesting that while the T790M mutation may affect inhibition by erlotinib and gefitinib , it may not affect inhibition of EGFR by compounds similar to lapatinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [151, 156], "tok_span": [30, 34]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [191, 200], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [151, 156], "obj_char_span": [50, 59], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [151, 156], "obj_char_span": [191, 200], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "One of the proposed mechanisms of resistance to gefitinib and erlotinib is the T790M mutation on exon 20 .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [62, 71], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [79, 84], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [79, 84], "obj_char_span": [62, 71], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "A randomized phase II trial compared erlotinib to erlotinib plus bevacizumab in patients with activating EGFR mutations ( defined as exon 19 deletion and exon 21 L858R point mutations ) and advanced stage NSCLC ( n = 152 ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [6, 10]}, {"name": "L858R", "ent_type": "variant", "char_span": [162, 167], "tok_span": [33, 37]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [162, 167], "obj_char_span": [37, 46], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [6, 10]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [162, 167], "obj_char_span": [50, 59], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "In addition , only half of this small cohort of patients with NSCLC with clinical resistance to gefitinib or erlotinib had the T790M substitution .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [109, 118], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [127, 132], "obj_char_span": [109, 118], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "In particular , H1975 cells contain a second mutation ( T790M ) reported to be linked to gefitinib resistance , but we found that these cells also responded poorly to cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [167, 176], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [56, 61], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [56, 61], "obj_char_span": [167, 176], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "However , adjuvant imatinib was not recommended for patients with primary GISTs containing PDGFRA D842V mutations .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [19, 27], "tok_span": [3, 5]}, {"name": "D842V", "ent_type": "variant", "char_span": [98, 103], "tok_span": [17, 21]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [98, 103], "obj_char_span": [19, 27], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Eight months after starting the treatment , when patients still responded to the dasatinib , authors sequenced kinase domain of DDR2 gene and identified the S768R mutation .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [81, 90], "tok_span": [13, 15]}, {"name": "S768R", "ent_type": "variant", "char_span": [157, 162], "tok_span": [28, 32]}], "relation_list": [{"subject": "S768R", "object": "dasatinib", "sbj_char_span": [157, 162], "obj_char_span": [81, 90], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Consistent with this , we found that the introduction of R1275Q into EML4-ALK had no negative impact on sensitivity to crizotinib ( IC50 47 ± 8 nm ) . ", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [119, 129], "tok_span": [28, 32]}, {"name": "R1275Q", "ent_type": "variant", "char_span": [57, 63], "tok_span": [10, 14]}], "relation_list": [{"subject": "R1275Q", "object": "crizotinib", "sbj_char_span": [57, 63], "obj_char_span": [119, 129], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "In vitro assays have also demonstrated L1196M gatekeeper mutation to be the major mechanism for crizotinib resistance ( Ou , 2011 ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [96, 106], "tok_span": [20, 24]}, {"name": "L1196M", "ent_type": "variant", "char_span": [39, 45], "tok_span": [6, 10]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [39, 45], "obj_char_span": [96, 106], "rel_type": "resistance", "sbj_tok_span": [6, 10], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "As shown in , the separation PMF in G2032R-ROS1 was much lower than that in WT-ROS1 , suggesting that serious crizotinib resistance could be induced by the mutation G2032R in the ROS1 tyrosine kinase .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [110, 120], "tok_span": [30, 34]}, {"name": "G2032R", "ent_type": "variant", "char_span": [165, 171], "tok_span": [41, 45]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [165, 171], "obj_char_span": [110, 120], "rel_type": "resistance", "sbj_tok_span": [41, 45], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "As a whole our findings confirmed the efficacy of ponatinib on the T315I mutation , but also highlighted the notion that ponatinib is effective on all types of imatinib-resistant CML cells , whatever their mode of resistance .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [9, 13]}, {"name": "T315I", "ent_type": "variant", "char_span": [67, 72], "tok_span": [15, 19]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [27, 31]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [67, 72], "obj_char_span": [50, 59], "rel_type": "response", "sbj_tok_span": [15, 19], "obj_tok_span": [9, 13]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [67, 72], "obj_char_span": [121, 130], "rel_type": "response", "sbj_tok_span": [15, 19], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Our results suggest that in addition to T315I patients , ponatinib could be widely used in resistant CML patients , whatever the supposed mode of resistance to first line ITKs .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [57, 66], "tok_span": [13, 17]}, {"name": "T315I", "ent_type": "variant", "char_span": [40, 45], "tok_span": [7, 11]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [40, 45], "obj_char_span": [57, 66], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Ponatinib is the only available drug that is designed to overcome T315I gatekeeper mutation and is efficient in inhibiting the mutant BCR-ABL. ", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [66, 71], "tok_span": [12, 16]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [66, 71], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Results showed that ponatinib has the highest binding affinity towards the T315I mutant BCR-ABL with a docking score of −11.050 kcal/mol while bosutinib , bafetinib , dasatinib , nilotinib and imatinib showed −5.513 kcal/mol , −4.689 kcal/mol , −4.702 kcal/mol , −3.772 kcal/mol , −3.593 kcal/mol and −3.78 kcal/mol , respectively ( ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [20, 29], "tok_span": [3, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [75, 80], "tok_span": [14, 18]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [75, 80], "obj_char_span": [20, 29], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Ponatinib contains an unique carbon–carbon triple bond linkage that avoids the steric hindrance to other drugs caused by the bulky isoleucine residue at position 315 in the T315I mutant .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "the T315I", "ent_type": "variant", "char_span": [169, 178], "tok_span": [34, 39]}], "relation_list": [{"subject": "the T315I", "object": "Ponatinib", "sbj_char_span": [169, 178], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [34, 39], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Ponatinib BCR-ABL with mutations , including T315I + + Sen et al", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [45, 50], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Interestingly , vandetanib has been shown recently to be well tolerated and highly active in children with locally advanced or metastatic medullary thyroid cancer in the context of a RET M918T mutation .", "entity_list": [{"name": "vandetanib", "ent_type": "drug", "char_span": [16, 26], "tok_span": [2, 6]}, {"name": "M918T", "ent_type": "variant", "char_span": [187, 192], "tok_span": [34, 38]}], "relation_list": [{"subject": "M918T", "object": "vandetanib", "sbj_char_span": [187, 192], "obj_char_span": [16, 26], "rel_type": "response", "sbj_tok_span": [34, 38], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "The point mutation T790M of the EGFR gene and MET amplification are known to be involved in the majority of cases of acquired resistance to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [140, 149], "tok_span": [28, 32]}, {"name": "T790M", "ent_type": "variant", "char_span": [19, 24], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [19, 24], "obj_char_span": [140, 149], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "The drug resistance mutation T790M was detected in CTCs collected from patients with EGFR mutations that had received tyrosine kinase inhibitors Gefitinib ( Iressa ) or Erlotinib ( Tarceva ) .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [145, 154], "tok_span": [25, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [29, 34], "tok_span": [4, 8]}, {"name": "Iressa", "ent_type": "drug", "char_span": [157, 163], "tok_span": [29, 32]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [29, 34], "obj_char_span": [145, 154], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [25, 28]}, {"subject": "T790M", "object": "Iressa", "sbj_char_span": [29, 34], "obj_char_span": [157, 163], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "Some data suggest that patients with EGFR exon 19 deletions are more susceptible to the activity of reversible EGFR-TKIs compared to those with the exon 21 L858R mutation. , Further studies then compared first-generation EGFR-TKIs ( erlotinib and gefitinib ) to chemotherapy in patients with EGFR activating mutations in advanced NSCLC .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [233, 242], "tok_span": [48, 52]}, {"name": "L858R", "ent_type": "variant", "char_span": [156, 161], "tok_span": [29, 33]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [156, 161], "obj_char_span": [233, 242], "rel_type": "sensitivity", "sbj_tok_span": [29, 33], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "Inhibition of EGFR cell lines by afatinib compared to erlotinib as shown by EC50 values Wild-type L858R mutation L858R + T790M", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [54, 63], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [98, 103], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [121, 126], "tok_span": [33, 37]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [98, 103], "obj_char_span": [54, 63], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [121, 126], "obj_char_span": [54, 63], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "The T790M mutation accounts for approximately 50 % of cases in which acquired resistance to erlotinib or gefitinib occurs , , .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [92, 101], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [92, 101], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "BMS-690514 , a reversible oral inhibitor of EGFR , HER-2 and −4 , VEGFRs-1 to −3 , showed antitumour activity in tumour xenograft models and in cell lines containing the EGFR T790M mutation , suggesting a role against erlotinib-resistant tumours .", "entity_list": [{"name": "against erlotinib-resistant", "ent_type": "drug", "char_span": [210, 237], "tok_span": [53, 60]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [170, 180], "tok_span": [43, 48]}], "relation_list": [{"subject": "EGFR T790M", "object": "against erlotinib-resistant", "sbj_char_span": [170, 180], "obj_char_span": [210, 237], "rel_type": "resistance or non-response", "sbj_tok_span": [43, 48], "obj_tok_span": [53, 60]}], "umls_entity_list": []}, {"text": "Since a secondary T790M mutation was found on a liver biopsy , but not in the CSF , the patient received erlotinib , and the brain metastasis responded well to treatment .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [105, 114], "tok_span": [24, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [18, 23], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [18, 23], "obj_char_span": [105, 114], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "This molecular change had been found in samples with gefitinib or erlotinib resistance in vivo or in vitro . c-MET amplification has also occasionally been found to coexist with EGFR T790M mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [14, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [183, 188], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [183, 188], "obj_char_span": [66, 75], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "We did not detect any V600E BRAF mutations in our study while the frequency of BRAF mutations was 12 % in the aforementioned study of cetuximab plus chemotherapy in advanced OGJ cancer patients .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [134, 143], "tok_span": [27, 31]}, {"name": "V600E", "ent_type": "variant", "char_span": [22, 27], "tok_span": [5, 8]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [22, 27], "obj_char_span": [134, 143], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 8], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "One mechanism to resistance was recently elucidated : cetuximab resistant cells contain an EGFR mutation in the extracellular domain ( S492R ) that impairs cetuximab , but not epidermal growth factor (EGF) binding .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [54, 63], "tok_span": [8, 12]}, {"name": "S492R", "ent_type": "variant", "char_span": [135, 140], "tok_span": [23, 27]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [156, 165], "tok_span": [30, 34]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [135, 140], "obj_char_span": [54, 63], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [8, 12]}, {"subject": "S492R", "object": "cetuximab", "sbj_char_span": [135, 140], "obj_char_span": [156, 165], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Montagut et al. reported an acquired EGFR ectodomain mutation ( S492R ) that prevented cetuximab binding , thus conferring resistance to this drug . ", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [87, 96], "tok_span": [22, 26]}, {"name": "S492R", "ent_type": "variant", "char_span": [64, 69], "tok_span": [15, 19]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [64, 69], "obj_char_span": [87, 96], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "This indicates that panitumumab may be effective in patients with the S492R mutation after failure of cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [102, 111], "tok_span": [21, 25]}, {"name": "S492R", "ent_type": "variant", "char_span": [70, 75], "tok_span": [13, 17]}, {"name": "panitumumab", "ent_type": "drug", "char_span": [20, 31], "tok_span": [3, 6]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [70, 75], "obj_char_span": [102, 111], "rel_type": "resistance", "sbj_tok_span": [13, 17], "obj_tok_span": [21, 25]}, {"subject": "S492R", "object": "panitumumab", "sbj_char_span": [70, 75], "obj_char_span": [20, 31], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Our molecular docking analysis revealed that ponatinib could target native or T674I FIP1L1-PDGFRα in the DFG-out ( inactive ) binding mode , similar to ponatinib docking in T315I Bcr-Abl . ", "entity_list": [{"name": "T674I", "ent_type": "variant", "char_span": [78, 83], "tok_span": [14, 18]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [45, 54], "tok_span": [6, 10]}, {"name": "in T315I", "ent_type": "variant", "char_span": [170, 178], "tok_span": [46, 51]}, {"name": "to ponatinib", "ent_type": "drug", "char_span": [149, 161], "tok_span": [40, 45]}], "relation_list": [{"subject": "in T315I", "object": "ponatinib", "sbj_char_span": [170, 178], "obj_char_span": [45, 54], "rel_type": "response", "sbj_tok_span": [46, 51], "obj_tok_span": [6, 10]}, {"subject": "in T315I", "object": "to ponatinib", "sbj_char_span": [170, 178], "obj_char_span": [149, 161], "rel_type": "response", "sbj_tok_span": [46, 51], "obj_tok_span": [40, 45]}], "umls_entity_list": []}, {"text": "Given the FDA approval of oral ponatinib in patients with refractory CML and Ph + ALL resistant to the first- and second-generation of TKIs , our findings warrant a clinical trial of ponatinib in imatinib-resistant CEL and other malignant disorders harboring T674I PDGFRα .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [196, 214], "tok_span": [44, 48]}, {"name": "T674I", "ent_type": "variant", "char_span": [259, 264], "tok_span": [55, 59]}], "relation_list": [{"subject": "T674I", "object": "imatinib-resistant", "sbj_char_span": [259, 264], "obj_char_span": [196, 214], "rel_type": "resistance", "sbj_tok_span": [55, 59], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "Heinrich and associates reported on the effect of crenolanib on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [87, 105], "tok_span": [17, 21]}, {"name": "D842V", "ent_type": "variant", "char_span": [106, 111], "tok_span": [21, 25]}], "relation_list": [{"subject": "D842V", "object": "imatinib-resistant", "sbj_char_span": [106, 111], "obj_char_span": [87, 105], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR T790M mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [73, 81], "tok_span": [12, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [249, 254], "tok_span": [44, 48]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [249, 254], "obj_char_span": [73, 81], "rel_type": "response", "sbj_tok_span": [44, 48], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Second generation EGFR TKIs e.g. , BIBW 2992 ( afatinib ) and PF00299804 ( dacomitinib ) , and third generation EGFR TKIs e.g. , CO-1686 and AZD9291 are irreversible inhibitors that could overcome the AR caused by T790M .", "entity_list": [{"name": "BIBW 2992", "ent_type": "drug", "char_span": [35, 44], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [214, 219], "tok_span": [61, 65]}, {"name": "afatinib", "ent_type": "drug", "char_span": [47, 55], "tok_span": [15, 17]}], "relation_list": [{"subject": "T790M", "object": "BIBW 2992", "sbj_char_span": [214, 219], "obj_char_span": [35, 44], "rel_type": "response", "sbj_tok_span": [61, 65], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [214, 219], "obj_char_span": [47, 55], "rel_type": "response", "sbj_tok_span": [61, 65], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "In contrast , ponatinib was designed to avoid binding with the side chain of T315I in native BCR-ABL , and instead forms beneficial van der Waals interactions with the isoleucine side chain of the T315I mutant .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [14, 23], "tok_span": [3, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [77, 82], "tok_span": [17, 21]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [77, 82], "obj_char_span": [14, 23], "rel_type": "response", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "These patients may respond to investigational agents , such as AP24534 or omacetaxine , and should pursue allogeneic stem cell transplantation.– There has been some concern about selecting for T315I with the increased use of second-generation TKIs . ", "entity_list": [{"name": "AP24534", "ent_type": "drug", "char_span": [63, 70], "tok_span": [11, 15]}, {"name": "for T315I", "ent_type": "variant", "char_span": [189, 198], "tok_span": [37, 42]}], "relation_list": [{"subject": "for T315I", "object": "AP24534", "sbj_char_span": [189, 198], "obj_char_span": [63, 70], "rel_type": "response", "sbj_tok_span": [37, 42], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "( D ) COS-7 cells with stable transduced expression of L858R or L858R+E884K mutant EGFR were tested in cellular cytotoxicity assay in vitro under drug treatment with either erlotinib or gefitinib at indicated concentrations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [186, 195], "tok_span": [46, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [55, 60], "tok_span": [12, 16]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [173, 182], "tok_span": [41, 45]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [55, 60], "obj_char_span": [186, 195], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [46, 50]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [55, 60], "obj_char_span": [173, 182], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [41, 45]}], "umls_entity_list": []}, {"text": "T790M is a secondary mutation which endows gefitinib resistance to the L858R lesion .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [43, 52], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}, {"name": "L858R", "ent_type": "variant", "char_span": [71, 76], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [0, 5], "obj_char_span": [43, 52], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [11, 15]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [71, 76], "obj_char_span": [43, 52], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Further study could be the mono/combinations of chemotherapy with gefitinib or inhibitors of the AKT pathway which should be tested in vitro in cell lines and in vivo in tumor xenografts with EGFR L858R mutations to determine whether these may be additive or synergistic .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [197, 202], "tok_span": [39, 43]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [197, 202], "obj_char_span": [66, 75], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "EGFR L858R , one of the most common activating mutations , allows gefitinib to move deeper into the binding pocket , enhancing the interaction between gefitinib and the receptor . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [15, 19]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [151, 160], "tok_span": [31, 35]}, {"name": "L858R", "ent_type": "variant", "char_span": [5, 10], "tok_span": [1, 5]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [5, 10], "obj_char_span": [66, 75], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [15, 19]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [5, 10], "obj_char_span": [151, 160], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "Doody and colleagues studied the activity of cetuximab with NSCLC lines bearing both wild-type EGFR and those with activating mutations in the intracellular kinase domain : not only those known to confer sensitivity to gefitinib and erlotinib ( L858R and delL747-T753insS ) but also the TKI-resistant mutation T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [219, 228], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [310, 315], "tok_span": [74, 78]}, {"name": "L858R", "ent_type": "variant", "char_span": [245, 250], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [310, 315], "obj_char_span": [219, 228], "rel_type": "resistance or non-response", "sbj_tok_span": [74, 78], "obj_tok_span": [40, 44]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [245, 250], "obj_char_span": [219, 228], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "The resistance of PC9/AB2 cells to gefitinib has been proved to maintain for at least one year in the medium without gefitinib and there is no T790M in PC9/AB2 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [35, 44], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [143, 148], "tok_span": [36, 40]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [117, 126], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [143, 148], "obj_char_span": [35, 44], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [143, 148], "obj_char_span": [117, 126], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "While drug-sensitive L858R bearing lungs showed degenerating tumor after erlotinib ( ) , EGFRL858R+T790M bearing tumors contained virtually all viable cells with no treatment effect ( and ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [73, 82], "tok_span": [15, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [21, 26], "tok_span": [4, 8]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [21, 26], "obj_char_span": [73, 82], "rel_type": "sensitivity", "sbj_tok_span": [4, 8], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "TP53 : Not done Yes PR1.9 erlotinib , cetuximab PD2 9 Adenocarcinoma L858R ( exon 21 ) Sensitive PIK3CA : No", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [26, 35], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [69, 74], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [69, 74], "obj_char_span": [26, 35], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "TP53 : Not done Yes SD 11.5 erlotinib , dasatinib PD2 10 Adenocarcinoma L858R ( exon 21 ) Sensitive PIK3CA : Not done", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [28, 37], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [72, 77], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [72, 77], "obj_char_span": [28, 37], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Thus , Inukai et al proposed that , although the detection of T790M positive tumor cells may be useful for predicting the clinical efficacy of gefitinib , gefitinib treatment might result in the selection of T790M mutant cells and that even a small fraction of T790M positive tumor cells at the beginning of treatment could lead to clinical resistance as a result of the selective proliferation of T790M mutant cells .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [143, 152], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [62, 67], "tok_span": [14, 18]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [155, 164], "tok_span": [35, 39]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [62, 67], "obj_char_span": [143, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [30, 34]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [62, 67], "obj_char_span": [155, 164], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "In addition to the presence of the T790M variation , L747S , D761Y , and G796A variations were identified in NSCLC patients with acquired resistance to gefitinib ; the G796A variant is especially known to cause strong resistance to EGFR-TKIs .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [152, 161], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [35, 40], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [35, 40], "obj_char_span": [152, 161], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "The mutant 2369 T peak was small , possibly because gefitinib had been discontinued in this patient for 4 mo at the time pleural fluid tumor cells were collected ; thus , there was no selective advantage conferred upon cells bearing the T790M mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [52, 61], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [237, 242], "tok_span": [47, 51]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [237, 242], "obj_char_span": [52, 61], "rel_type": "resistance or non-response", "sbj_tok_span": [47, 51], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "EGFR Mutants Containing the T790M Mutation Are Resistant to Inhibition by Gefitinib or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or EGFR mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [74, 83], "tok_span": [17, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [6, 10]}, {"name": "L858R", "ent_type": "variant", "char_span": [235, 240], "tok_span": [53, 57]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [28, 33], "obj_char_span": [74, 83], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [17, 20]}, {"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [235, 240], "obj_char_span": [74, 83], "rel_type": "sensitivity", "sbj_tok_span": [53, 57], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "This compound was previously found to be active against EGFR containing the exon 20 point mutation T790M , associated with resistance to gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [137, 146], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [99, 104], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [99, 104], "obj_char_span": [137, 146], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Cells expressing wild-type , L858R , or D770_N771insNPG EGFR were treated for 2 h with the indicated concentrations of gefitinib or CL-387,785 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [119, 128], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [29, 34], "tok_span": [6, 10]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [29, 34], "obj_char_span": [119, 128], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "An objective response rate of 25 % for gefitinib treatment was reported in 16 patients with exon 20 mutations , and it was much lower than the response rate of patients with deletions in exon 19 and L858R mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [39, 48], "tok_span": [8, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [199, 204], "tok_span": [40, 44]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [199, 204], "obj_char_span": [39, 48], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant .", "entity_list": [{"name": "for Gefitinib", "ent_type": "drug", "char_span": [323, 336], "tok_span": [82, 86]}, {"name": "T790M", "ent_type": "variant", "char_span": [11, 16], "tok_span": [4, 8]}, {"name": "for Gefitinib", "ent_type": "drug", "char_span": [434, 447], "tok_span": [104, 108]}, {"name": "for Erlotinib", "ent_type": "drug", "char_span": [126, 139], "tok_span": [35, 39]}, {"name": "L858R", "ent_type": "variant", "char_span": [64, 69], "tok_span": [18, 22]}, {"name": "for Erlotinib", "ent_type": "drug", "char_span": [229, 242], "tok_span": [56, 60]}], "relation_list": [{"subject": "T790M", "object": "for Gefitinib", "sbj_char_span": [11, 16], "obj_char_span": [323, 336], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [82, 86]}, {"subject": "T790M", "object": "for Gefitinib", "sbj_char_span": [11, 16], "obj_char_span": [434, 447], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [104, 108]}, {"subject": "L858R", "object": "for Erlotinib", "sbj_char_span": [64, 69], "obj_char_span": [126, 139], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [35, 39]}, {"subject": "L858R", "object": "for Erlotinib", "sbj_char_span": [64, 69], "obj_char_span": [229, 242], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [56, 60]}, {"subject": "T790M", "object": "for Erlotinib", "sbj_char_span": [11, 16], "obj_char_span": [126, 139], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [35, 39]}, {"subject": "T790M", "object": "for Erlotinib", "sbj_char_span": [11, 16], "obj_char_span": [229, 242], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [56, 60]}], "umls_entity_list": []}, {"text": "In addition , only half of this small cohort of patients with NSCLC with clinical resistance to gefitinib or erlotinib had the T790M substitution .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [96, 105], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [127, 132], "obj_char_span": [96, 105], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "The tumor progressed and developed an additional T790M mutation after nine months of gefitinib treatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [49, 54], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [49, 54], "obj_char_span": [85, 94], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Citation : Gow CH , Shih JY , Chang YL , Yu CJ ( 2005 ) Acquired gefitinib-resistant mutation of epidermal growth factor receptor in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [65, 84], "tok_span": [22, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [205, 210], "tok_span": [49, 53]}, {"name": "gefitinib-sensitive", "ent_type": "drug", "char_span": [176, 195], "tok_span": [42, 48]}], "relation_list": [{"subject": "L858R", "object": "gefitinib-resistant", "sbj_char_span": [205, 210], "obj_char_span": [65, 84], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [22, 28]}, {"subject": "L858R", "object": "gefitinib-sensitive", "sbj_char_span": [205, 210], "obj_char_span": [176, 195], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [42, 48]}], "umls_entity_list": []}, {"text": "In NSCLC , resistance to the EGFR TKI gefitinib is associated with the positive selection of cells harbouring the gatekeeper T790M mutation known to confer insensitivity to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [38, 47], "tok_span": [9, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [125, 130], "tok_span": [28, 32]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [173, 182], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [125, 130], "obj_char_span": [38, 47], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [125, 130], "obj_char_span": [173, 182], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "As previously demonstrated , cells with the deletion mutant and the point mutation L858R were inhibited by the TKIs gefitinib and erlotinib , while the exon 20 insertion mutation was resistant . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [116, 125], "tok_span": [23, 27]}, {"name": "L858R", "ent_type": "variant", "char_span": [83, 88], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [83, 88], "obj_char_span": [116, 125], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Male 68 Moderately differentiated adenocarcinoma little fine counts 80 Gefitinib SD 10 26 E709K , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [71, 80], "tok_span": [10, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [98, 103], "tok_span": [21, 25]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [98, 103], "obj_char_span": [71, 80], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "The interaction between TM4SF5 and EGFR is observed by a co-immunoprecipitation approach using NSCLC expressing TM4SF5 , where the interaction is positively correlated with the gefitinib resistance even without EGFR mutation ( e.g. , T790M ) following TM4SF5 overexpression .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [234, 239], "tok_span": [49, 53]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [234, 239], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [49, 53], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "As compared to the large number of secondary resistance mutations noted in acquired imatinib resistance in CML , in the case of EGFR-TK , there are currently only several documented resistance point mutations to gefitinib and erlotinib , including T790M , L747S and D761Y .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [226, 235], "tok_span": [42, 46]}, {"name": "T790M", "ent_type": "variant", "char_span": [248, 253], "tok_span": [48, 52]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [248, 253], "obj_char_span": [226, 235], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "While T790M is found in about half of patients with acquired resistance to erlotinib and gefitinib , the other mechanism of resistance – MET amplification – makes up about 5 % –10 % of these patients .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [75, 84], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [6, 11], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [6, 11], "obj_char_span": [75, 84], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The subsequent decrease in potency for Erlotinib against the oncogenic EGFR L858R + E884K double mutant correlates well with the increased global connectivity of the hub residues ( – wild type , – L858R + E884K mutant ) .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [39, 48], "tok_span": [6, 9]}, {"name": "L858R", "ent_type": "variant", "char_span": [76, 81], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [76, 81], "obj_char_span": [39, 48], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "( c ) Western blot analysis of the expression levels of WT , L858R , and Δ746–750 tEGFRs in the presence and absence of the EGFR inhibitor erlotinib .", "entity_list": [{"name": "inhibitor erlotinib", "ent_type": "drug", "char_span": [129, 148], "tok_span": [35, 40]}, {"name": "L858R", "ent_type": "variant", "char_span": [61, 66], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "inhibitor erlotinib", "sbj_char_span": [61, 66], "obj_char_span": [129, 148], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [35, 40]}], "umls_entity_list": []}, {"text": "A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( T315I ) following imatinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [387, 396], "tok_span": [79, 83]}, {"name": "T790M", "ent_type": "variant", "char_span": [369, 374], "tok_span": [73, 77]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [369, 374], "obj_char_span": [387, 396], "rel_type": "resistance or non-response", "sbj_tok_span": [73, 77], "obj_tok_span": [79, 83]}], "umls_entity_list": []}, {"text": "Tyrosine kinase inhibitors ( TKIs ) targeting the epidermal growth factor receptor (EGFR) , such as gefitinib and erlotinib , have shown remarkable activity in the patients with NSCLC , and particularly these TKIs are more effective to NSCLC with EGFR mutations in 19 exon ( in-frame deletions ) and exon 21 ( L858R point mutation ) , which are found to be more prevalent in Asian patients .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [114, 123], "tok_span": [25, 29]}, {"name": "L858R", "ent_type": "variant", "char_span": [310, 315], "tok_span": [66, 70]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [310, 315], "obj_char_span": [114, 123], "rel_type": "sensitivity", "sbj_tok_span": [66, 70], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Pan J et al reported that EXEL-0862 is effective against Gleevec-resistant D816V KIT and T674I PDGFRα ( 2007 ) .", "entity_list": [{"name": "Gleevec-resistant", "ent_type": "drug", "char_span": [57, 74], "tok_span": [14, 19]}, {"name": "T674I", "ent_type": "variant", "char_span": [89, 94], "tok_span": [26, 30]}], "relation_list": [{"subject": "T674I", "object": "Gleevec-resistant", "sbj_char_span": [89, 94], "obj_char_span": [57, 74], "rel_type": "resistance", "sbj_tok_span": [26, 30], "obj_tok_span": [14, 19]}], "umls_entity_list": []}, {"text": "BT474 lapatinib-resistant cells acquire E542K PIK3CA mutation .", "entity_list": [{"name": "lapatinib-resistant", "ent_type": "drug", "char_span": [6, 25], "tok_span": [3, 8]}, {"name": "E542K", "ent_type": "variant", "char_span": [40, 45], "tok_span": [10, 14]}], "relation_list": [{"subject": "E542K", "object": "lapatinib-resistant", "sbj_char_span": [40, 45], "obj_char_span": [6, 25], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [3, 8]}], "umls_entity_list": []}, {"text": "Similarly to BT474 LR cells with acquired E542K mutation , cells with the other hotspot mutations showed a blunted inhibitor response of PI3K signaling to lapatinib with persistent PI3K-Akt signaling ( Figure A ) .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [155, 164], "tok_span": [35, 38]}, {"name": "E542K", "ent_type": "variant", "char_span": [42, 47], "tok_span": [9, 13]}], "relation_list": [{"subject": "E542K", "object": "lapatinib", "sbj_char_span": [42, 47], "obj_char_span": [155, 164], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [35, 38]}], "umls_entity_list": []}, {"text": "First , GIST mutational status appears to be important , and there is a consensus that patients with the imatinib-insensitive D842V mutation of PDGFRA should not receive adjuvant imatinib .", "entity_list": [{"name": "imatinib-insensitive", "ent_type": "drug", "char_span": [105, 125], "tok_span": [21, 25]}, {"name": "D842V", "ent_type": "variant", "char_span": [126, 131], "tok_span": [25, 29]}, {"name": "imatinib", "ent_type": "drug", "char_span": [179, 187], "tok_span": [37, 39]}], "relation_list": [{"subject": "D842V", "object": "imatinib-insensitive", "sbj_char_span": [126, 131], "obj_char_span": [105, 125], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [21, 25]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [126, 131], "obj_char_span": [179, 187], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "In a recent report , the c-KIT mutation L576P was associated with resistance to multiple KIT inhibitors including imatinib , nilotinib , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the KIT L576P mutation after treatment with dasatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [114, 122], "tok_span": [25, 27]}, {"name": "L576P", "ent_type": "variant", "char_span": [40, 45], "tok_span": [11, 15]}, {"name": "nilotinib", "ent_type": "drug", "char_span": [125, 134], "tok_span": [28, 31]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [40, 45], "obj_char_span": [114, 122], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [25, 27]}, {"subject": "L576P", "object": "nilotinib", "sbj_char_span": [40, 45], "obj_char_span": [125, 134], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "The BRAF V600E mutation has been described as a predictor of tumor aggressiveness in metastatic disease and also of low RRs to cetuximab and panitumumab .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [141, 152], "tok_span": [31, 34]}, {"name": "V600E", "ent_type": "variant", "char_span": [9, 14], "tok_span": [2, 5]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [9, 14], "obj_char_span": [141, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [2, 5], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "Moreover , the presence of the V600E mutation in the BRAF gene is more and more frequently taken into consideration before patient targeted therapy qualification , because wild-type BRAF is required for a response to panitumumab or cetuximab .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [217, 228], "tok_span": [40, 43]}, {"name": "V600E", "ent_type": "variant", "char_span": [31, 36], "tok_span": [6, 9]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [31, 36], "obj_char_span": [217, 228], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 9], "obj_tok_span": [40, 43]}], "umls_entity_list": []}, {"text": "G1202R EML-ALKpm A mutation-specific strong H-bond pulls crizotinib out of the position found in the non-crizotinib resistant EML-ALK fusion gene 1151Tins Thr insertion is predicted to alter ATP binding to ALK", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [57, 67], "tok_span": [20, 24]}, {"name": "G1202R", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}, {"name": "non-crizotinib", "ent_type": "drug", "char_span": [101, 115], "tok_span": [31, 37]}], "relation_list": [{"subject": "G1202R", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [57, 67], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [20, 24]}, {"subject": "G1202R", "object": "non-crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [101, 115], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [31, 37]}], "umls_entity_list": []}, {"text": "This suggests that F1174L mutation affects the binding of crizotinib and makes the backbone more flexible to move . ", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [58, 68], "tok_span": [12, 16]}, {"name": "F1174L", "ent_type": "variant", "char_span": [19, 25], "tok_span": [3, 7]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [19, 25], "obj_char_span": [58, 68], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "In a subset of patients with exon 19 and L858R mutations , the median PFS was 13.6 months for afatinib , compared with 6.9 months for chemotherapy ( HR = 0.47 , 95 % CI 0.34–0.65 , P & lt ; 0.0001 ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [94, 102], "tok_span": [24, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [41, 46], "tok_span": [9, 13]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [41, 46], "obj_char_span": [94, 102], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Even knock-down of the T790M transcript by siRNAs , when combined with afatinib , was efficacious in controlling T790M-mutant , lung cancer cells .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [71, 79], "tok_span": [18, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [23, 28], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [23, 28], "obj_char_span": [71, 79], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "However , for some patients , especially those possessing the T315I kinase domain mutation , ponatinib ( Iclusig® ) will be the ideal TKI .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [93, 102], "tok_span": [18, 22]}, {"name": "T315I", "ent_type": "variant", "char_span": [62, 67], "tok_span": [10, 14]}, {"name": "Iclusig®", "ent_type": "drug", "char_span": [105, 113], "tok_span": [23, 28]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [62, 67], "obj_char_span": [93, 102], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [18, 22]}, {"subject": "T315I", "object": "Iclusig®", "sbj_char_span": [62, 67], "obj_char_span": [105, 113], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [23, 28]}], "umls_entity_list": []}, {"text": "Overcoming both losses of an active-site hydrogen bond and the steric hindrance caused by the T315I mutation were the main focus during the design process of ponatinib . ", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [158, 167], "tok_span": [34, 38]}, {"name": "T315I", "ent_type": "variant", "char_span": [94, 99], "tok_span": [20, 24]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [94, 99], "obj_char_span": [158, 167], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "In addition , the recently approved ponatinib is active against the most common mutation that causes resistance to both first and second generation ABL TKIs , the “gatekeeper” T315I mutation ( Table ; Figure ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [36, 45], "tok_span": [6, 10]}, {"name": "“gatekeeper” T315I", "ent_type": "variant", "char_span": [163, 181], "tok_span": [32, 41]}], "relation_list": [{"subject": "“gatekeeper” T315I", "object": "ponatinib", "sbj_char_span": [163, 181], "obj_char_span": [36, 45], "rel_type": "response", "sbj_tok_span": [32, 41], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Doody and colleagues studied the activity of cetuximab with NSCLC lines bearing both wild-type EGFR and those with activating mutations in the intracellular kinase domain : not only those known to confer sensitivity to gefitinib and erlotinib ( L858R and delL747-T753insS ) but also the TKI-resistant mutation T790M .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [233, 242], "tok_span": [45, 49]}, {"name": "L858R", "ent_type": "variant", "char_span": [245, 250], "tok_span": [50, 54]}, {"name": "T790M", "ent_type": "variant", "char_span": [310, 315], "tok_span": [74, 78]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [245, 250], "obj_char_span": [233, 242], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [45, 49]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [310, 315], "obj_char_span": [233, 242], "rel_type": "resistance or non-response", "sbj_tok_span": [74, 78], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "Potential MS-5 effects were analyzed in ( 1 ) two imatinib-resistant UT-7-11 clones harboring the E255K mutation compared with non mutagenized UT-7-11 control and in ( 2 ) two ponatinib-resistant UT-7-315 clones harboring the T315I mutation alone compared with non mutagenized UT-7-315 control .", "entity_list": [{"name": "ponatinib-resistant", "ent_type": "drug", "char_span": [176, 195], "tok_span": [45, 51]}, {"name": "T315I", "ent_type": "variant", "char_span": [226, 231], "tok_span": [59, 63]}], "relation_list": [{"subject": "T315I", "object": "ponatinib-resistant", "sbj_char_span": [226, 231], "obj_char_span": [176, 195], "rel_type": "response", "sbj_tok_span": [59, 63], "obj_tok_span": [45, 51]}], "umls_entity_list": []}, {"text": "Overall , these data suggest that T315I mutants , supported by a stromal niche , could survive ponatinib through interactions mediated by direct contact or soluble factors .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [20, 24]}, {"name": "T315I", "ent_type": "variant", "char_span": [34, 39], "tok_span": [6, 10]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [34, 39], "obj_char_span": [95, 104], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "In addition , acquired resistance caused by a second site substitution , T790M in exon 20 , results in poorly gefitinib activity , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [110, 119], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [73, 78], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [73, 78], "obj_char_span": [110, 119], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "If an increase in BIM expression is important for gefitinib induced apoptosis , it should be suppressed upon treatment of cell lines expressing the resistant T790M EGFR mutation with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [158, 163], "tok_span": [29, 33]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [183, 192], "tok_span": [36, 40]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [158, 163], "obj_char_span": [50, 59], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [158, 163], "obj_char_span": [183, 192], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "These results confirm that up-regulation of BIM correlates with effective TKI induced apoptosis and that T790M suppresses this process in gefitinib treated cells .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [138, 147], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [105, 110], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [105, 110], "obj_char_span": [138, 147], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Bottom : Expression of EGFR in Ba/F3 cells expressing L858R , L858R-L747S #1–4 , or L858R-T790M . ( E ) Gefitinib release assay .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [104, 113], "tok_span": [47, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [54, 59], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [54, 59], "obj_char_span": [104, 113], "rel_type": "sensitivity", "sbj_tok_span": [14, 18], "obj_tok_span": [47, 50]}], "umls_entity_list": []}, {"text": "BIM expression correlated with the amount of apoptosis in L858R , L858R-L747S , and L858R-T790M cells . ( B ) Modulation of signaling following gefitinib treatment in Ba/F3 cells expressing EGFR mutants .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [144, 153], "tok_span": [45, 49]}, {"name": "L858R", "ent_type": "variant", "char_span": [58, 63], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [58, 63], "obj_char_span": [144, 153], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "For example , HCC827 cells undergo MET amplification and AXL induction upon adaption to gefitinib , , , and PC9 cells acquire the T790M mutation in EGFR that confers resistance to erlotinib and gefitinib . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [88, 97], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [130, 135], "tok_span": [31, 35]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [194, 203], "tok_span": [47, 51]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [130, 135], "obj_char_span": [88, 97], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 35], "obj_tok_span": [18, 22]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [130, 135], "obj_char_span": [194, 203], "rel_type": "resistance or non-response", "sbj_tok_span": [31, 35], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( afatinib ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [123, 132], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [74, 79], "tok_span": [21, 25]}, {"name": "L858R", "ent_type": "variant", "char_span": [57, 62], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [74, 79], "obj_char_span": [123, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [35, 39]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [123, 132], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Kim and colleagues demonstrated that the combination of lapatinib with cetuximab overcame gefitinib resistance due to the secondary T790M mutation in NSCLC by inducing enhanced cytotoxicity both in vitro and in vivo .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [132, 137], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [132, 137], "obj_char_span": [90, 99], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "PFS was 4.4 months , whereas median overall survival was 19 months ; two patients with acquired T790M mutations had SD for 9 months and 1 month , respectively The most common afatinib related toxicities were diarrhea in all patients and rash/acne in 91.9 % of patients LUX-Lung 7 , NCT01466660 IIb Yes First-line Afatinib versus gefitinib PFS ; DCR – –", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [329, 338], "tok_span": [80, 84]}, {"name": "T790M", "ent_type": "variant", "char_span": [96, 101], "tok_span": [19, 23]}, {"name": "afatinib", "ent_type": "drug", "char_span": [175, 183], "tok_span": [37, 39]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [96, 101], "obj_char_span": [329, 338], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [80, 84]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [96, 101], "obj_char_span": [175, 183], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "Cytology showed the development of right pleural effusion after gefitinib treatment , and a second mutation of T790M was found in the primary lesion .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [64, 73], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [111, 116], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [111, 116], "obj_char_span": [64, 73], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "A secondary point mutation in exon 20 of EGFR ( T790M ) is associated with acquired resistance to gefitinib or Erlotinib , but this can be overcome by the irreversible EGFR-tyrosine kinase inhibitor BIBW2992 ( BIBW ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [98, 107], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [48, 53], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [48, 53], "obj_char_span": [98, 107], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "Patient nos. 18 and 20 who received gefitinib before metachronous metastasis developed metastatic tumours , which were either wild type in respect to EGFR mutation status ( no. 18 ) or had acquired resistance because of the T790M EGFR mutation ( no. 20 ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [36, 45], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [224, 229], "tok_span": [45, 49]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [224, 229], "obj_char_span": [36, 45], "rel_type": "resistance or non-response", "sbj_tok_span": [45, 49], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "For tyrosine kinase inhibitors ( TKIs ) , mutations within the ATP pocket of the kinase domain may affect the interaction of the drug with its target : for example , the single amino acid mutation tyrosine/methionine ( T790M ) in the ATP binding pocket of the EGFR mediates secondary resistance to the EGFR TKIs erlotinib and gefitinib in non-small cell lung cancer ( NSCLC ) . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [326, 335], "tok_span": [67, 71]}, {"name": "T790M", "ent_type": "variant", "char_span": [219, 224], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [219, 224], "obj_char_span": [326, 335], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 45], "obj_tok_span": [67, 71]}], "umls_entity_list": []}, {"text": "In addition , other EGFR mutations have also demonstrated contribution to the development of drug resistance to erlotinib and gefitinib , including secondary EGFR kinase mutations , L858R mutations , and secondary D761Y point mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [126, 135], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [182, 187], "tok_span": [33, 37]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [112, 121], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [182, 187], "obj_char_span": [126, 135], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [22, 26]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [182, 187], "obj_char_span": [112, 121], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Second-generation TKIs that irreversibly inhibit the EGFR TKI domain may offer the potential for overcoming the resistance of T790M mutation to erlotinib and gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [158, 167], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [126, 131], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [126, 131], "obj_char_span": [158, 167], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Similarly , the T790M point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib , which are used to treat non-small cell lung cancer .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [142, 151], "tok_span": [26, 30]}, {"name": "T790M", "ent_type": "variant", "char_span": [16, 21], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [16, 21], "obj_char_span": [142, 151], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Moreover , serial genotyping of circulating lung cancer cells during gefitinib therapy demonstrated the emergence of the kinase inhibitor resistance–associated mutation T790M at increasing allelic ratios , coinciding with clinical relapse .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [69, 78], "tok_span": [10, 14]}, {"name": "mutation T790M", "ent_type": "variant", "char_span": [160, 174], "tok_span": [25, 30]}], "relation_list": [{"subject": "mutation T790M", "object": "gefitinib", "sbj_char_span": [160, 174], "obj_char_span": [69, 78], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 30], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Acquired resistance , including EGFR secondary mutations ( T790M and other rare mutations ) , MET gene amplification , PTEN gene downregulation , high-level hepatocyte growth factor expression , epithelial–mesenchymal transition , and conversion to small cell lung cancer , – continues to restrict the durable long-term outcomes of erlotinib .", "entity_list": [{"name": "of erlotinib", "ent_type": "drug", "char_span": [329, 341], "tok_span": [60, 65]}, {"name": "T790M", "ent_type": "variant", "char_span": [59, 64], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "of erlotinib", "sbj_char_span": [59, 64], "obj_char_span": [329, 341], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 13], "obj_tok_span": [60, 65]}], "umls_entity_list": []}, {"text": "A recent study demonstrated that using a combination of erlotinib and cetuximab reversed the drug resistance in NSCLC in T790M and L858R mutation lung cancer cell lines ( Wang et al. , ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [56, 65], "tok_span": [9, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [131, 136], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [121, 126], "tok_span": [25, 29]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [70, 79], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [131, 136], "obj_char_span": [56, 65], "rel_type": "sensitivity", "sbj_tok_span": [30, 34], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [121, 126], "obj_char_span": [56, 65], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "cetuximab", "sbj_char_span": [121, 126], "obj_char_span": [70, 79], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "On the basis of this study , in May 2013 the U.S Food and Drug Administration ( FDA ) approved erlotinib for use in patients with lung cancers harboring EGFR exon 19 deletions and EGFR L858R substitutions . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [185, 190], "tok_span": [40, 44]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [185, 190], "obj_char_span": [95, 104], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Finally , a recent study shows not only that EGFR mutations are statistically associated with Asian ethnicity and never-smoker status , but also that patients with EGFR exon 19 deletions have significantly longer median survival than patients with EGFR L858R mutation ( 34 vs. 8 months , p=0.01 ) after treatment with gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [331, 340], "tok_span": [68, 72]}, {"name": "L858R", "ent_type": "variant", "char_span": [253, 258], "tok_span": [42, 46]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [253, 258], "obj_char_span": [331, 340], "rel_type": "sensitivity", "sbj_tok_span": [42, 46], "obj_tok_span": [68, 72]}], "umls_entity_list": []}, {"text": "Di Nicolantonio et al. ( ) also demonstrated that introduction of the BRAF V600E allele could confer resistance to either cetuximab or panitumumab in wild-type BRAF colorectal cancer cells .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [122, 131], "tok_span": [27, 31]}, {"name": "V600E", "ent_type": "variant", "char_span": [75, 80], "tok_span": [18, 21]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [75, 80], "obj_char_span": [122, 131], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 21], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Thus , in two trials , administration of cetuximab to patients with this mutation was associated with a significantly better outcome than that seen in patients with other types of K-RAS mutations. , Indeed , patients with the G13D mutation appeared to benefit to approximately the same extent as patients with K-RAS wild-type tumors from the addition of cetuximab to first-line chemotherapy .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [41, 50], "tok_span": [8, 12]}, {"name": "G13D", "ent_type": "variant", "char_span": [226, 230], "tok_span": [44, 47]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [354, 363], "tok_span": [70, 74]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [226, 230], "obj_char_span": [41, 50], "rel_type": "resistance or non-response", "sbj_tok_span": [44, 47], "obj_tok_span": [8, 12]}, {"subject": "G13D", "object": "cetuximab", "sbj_char_span": [226, 230], "obj_char_span": [354, 363], "rel_type": "resistance or non-response", "sbj_tok_span": [44, 47], "obj_tok_span": [70, 74]}], "umls_entity_list": []}, {"text": "The T670I allele of c-Kit is a mutation originally identified in GIST patients with refractory responses to imatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [108, 116], "tok_span": [23, 25]}, {"name": "T670I", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [4, 9], "obj_char_span": [108, 116], "rel_type": "resistance", "sbj_tok_span": [1, 5], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "The second-line treatment , after imatinib failure , is provided by less specific kinase inhibitors , such as sunitinib that shows potency against imatinib-resistant KIT mutated in the ATP binding pocket ( V654A and T670I ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [34, 42], "tok_span": [7, 9]}, {"name": "V654A", "ent_type": "variant", "char_span": [206, 211], "tok_span": [41, 45]}, {"name": "imatinib-resistant", "ent_type": "drug", "char_span": [147, 165], "tok_span": [28, 32]}, {"name": "T670I", "ent_type": "variant", "char_span": [216, 221], "tok_span": [46, 50]}], "relation_list": [{"subject": "V654A", "object": "imatinib", "sbj_char_span": [206, 211], "obj_char_span": [34, 42], "rel_type": "resistance", "sbj_tok_span": [41, 45], "obj_tok_span": [7, 9]}, {"subject": "V654A", "object": "imatinib-resistant", "sbj_char_span": [206, 211], "obj_char_span": [147, 165], "rel_type": "resistance", "sbj_tok_span": [41, 45], "obj_tok_span": [28, 32]}, {"subject": "T670I", "object": "imatinib", "sbj_char_span": [216, 221], "obj_char_span": [34, 42], "rel_type": "resistance", "sbj_tok_span": [46, 50], "obj_tok_span": [7, 9]}, {"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [216, 221], "obj_char_span": [147, 165], "rel_type": "resistance", "sbj_tok_span": [46, 50], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Cells with an A829P c-Kit mutation are resistant to imatinib but are still sensitive to the tyrosine kinase inhibitors nilotinib and dasatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [52, 60], "tok_span": [14, 16]}, {"name": "A829P", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "A829P", "object": "imatinib", "sbj_char_span": [14, 19], "obj_char_span": [52, 60], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Panitumumab can still bind to an EGFR mutant S492R to which cetuximab can not bind to .", "entity_list": [{"name": "Panitumumab", "ent_type": "drug", "char_span": [0, 11], "tok_span": [0, 3]}, {"name": "S492R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "S492R", "object": "Panitumumab", "sbj_char_span": [45, 50], "obj_char_span": [0, 11], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Drug Company Activity against Activity against Ongoing trials Study phase Previous treatment other kinases L1196M mutation LDK378 ( ceritinib ) Novartis IFG-1R Yes NCT01772797 Phase I None c-MET NCT02040870 Phase I/II Crizotinib/chemotherapy NCT01685138 Phase II 0-3 lines of chemotherapy NCT01685060 Phase II Crizotinib or 1-3 lines of chemotherapy NCT01947608 Phase II Crizotinib NCT01964157 Phase II 1 line of chemotherapy NCT01828099 Phase III None NCT01828112 Phase III Crizotinib", "entity_list": [{"name": "Crizotinib/chemotherapy", "ent_type": "drug", "char_span": [218, 241], "tok_span": [60, 66]}, {"name": "L1196M", "ent_type": "variant", "char_span": [107, 113], "tok_span": [15, 19]}, {"name": "Crizotinib", "ent_type": "drug", "char_span": [310, 320], "tok_span": [87, 91]}, {"name": "Crizotinib", "ent_type": "drug", "char_span": [371, 381], "tok_span": [106, 110]}, {"name": "Crizotinib", "ent_type": "drug", "char_span": [475, 485], "tok_span": [138, 142]}], "relation_list": [{"subject": "L1196M", "object": "Crizotinib/chemotherapy", "sbj_char_span": [107, 113], "obj_char_span": [218, 241], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [60, 66]}, {"subject": "L1196M", "object": "Crizotinib", "sbj_char_span": [107, 113], "obj_char_span": [310, 320], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [87, 91]}, {"subject": "L1196M", "object": "Crizotinib", "sbj_char_span": [107, 113], "obj_char_span": [371, 381], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [106, 110]}, {"subject": "L1196M", "object": "Crizotinib", "sbj_char_span": [107, 113], "obj_char_span": [475, 485], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [138, 142]}], "umls_entity_list": []}, {"text": "This review details strategies pursued in circumventing T790M mediated drug resistance to EGFR inhibitors , which is the most common mechanism of acquired resistance , and focuses on the clinical development of second-generation EGFR inhibitors , and in particular afatinib ( BIBW2992 ; Boehringer Ingelheim ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [265, 273], "tok_span": [45, 47]}, {"name": "T790M", "ent_type": "variant", "char_span": [56, 61], "tok_span": [8, 12]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [56, 61], "obj_char_span": [265, 273], "rel_type": "response", "sbj_tok_span": [8, 12], "obj_tok_span": [45, 47]}], "umls_entity_list": []}, {"text": "Based on the clinical data of achievable plasma concentrations of continuous daily dosing of neratinib , dacomitinib and afatinib , it is thought that primary resistance to these agents will still be encountered for the EGFR T790M mutation as well as exon 20 insertions and clinical trial results thus far with the second-generation EGFR TKIs had generally supported this prediction with few exceptions ( see below ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [121, 129], "tok_span": [24, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [225, 230], "tok_span": [43, 47]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [225, 230], "obj_char_span": [121, 129], "rel_type": "response", "sbj_tok_span": [43, 47], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Thus , an alternate schedule of drug administration , such as intermittent or pulse high-dose therapy using afatinib to determine its activity against T790M ( NCT01647711 ) , is under investigation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [108, 116], "tok_span": [19, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [151, 156], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [151, 156], "obj_char_span": [108, 116], "rel_type": "response", "sbj_tok_span": [26, 30], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "AST1306 could potently inhibit the EGFR T790M mutant , exhibiting an IC50 value of 12 ± 2 nmol/L , which is similar to afatinib ( 10 nmol/L ) and approximately 500-fold more potent than lapatinib .", "entity_list": [{"name": "to afatinib", "ent_type": "drug", "char_span": [116, 127], "tok_span": [31, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [40, 45], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "to afatinib", "sbj_char_span": [40, 45], "obj_char_span": [116, 127], "rel_type": "response", "sbj_tok_span": [9, 13], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "KIT W557R V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib Nilotinib Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "entity_list": [{"name": "Dasatinib", "ent_type": "drug", "char_span": [117, 126], "tok_span": [51, 53]}, {"name": "L576P", "ent_type": "variant", "char_span": [18, 23], "tok_span": [12, 16]}], "relation_list": [{"subject": "L576P", "object": "Dasatinib", "sbj_char_span": [18, 23], "obj_char_span": [117, 126], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [51, 53]}], "umls_entity_list": []}, {"text": "The calculated free energies correlate with experimentally measured IC50 values and comparably ponatinib has better binding towards the mutation T315A ( −10.44 kcal/mol ) than T315I ( −10.35 kcal/mol ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [14, 18]}, {"name": "than T315I", "ent_type": "variant", "char_span": [171, 181], "tok_span": [37, 42]}], "relation_list": [{"subject": "than T315I", "object": "ponatinib", "sbj_char_span": [171, 181], "obj_char_span": [95, 104], "rel_type": "response", "sbj_tok_span": [37, 42], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "It has been speculated that a growing selection pressure in TKI treatment will promote the appearance of T315I mutations.– Novel compounds such as the aurora kinase inhibitors – including danusertib ( formerly PHA-739358 ) , homoharringtonine , and ponatinib – successfully target the T315I mutation .", "entity_list": [{"name": "and ponatinib", "ent_type": "drug", "char_span": [245, 258], "tok_span": [58, 63]}, {"name": "T315I", "ent_type": "variant", "char_span": [105, 110], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "and ponatinib", "sbj_char_span": [105, 110], "obj_char_span": [245, 258], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [58, 63]}], "umls_entity_list": []}, {"text": "Ponatinib is highly active in patients with Ph-positive leukemias , including those with BCR-ABL T315I mutations .", "entity_list": [{"name": "T315I", "ent_type": "variant", "char_span": [97, 102], "tok_span": [21, 25]}, {"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [97, 102], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [21, 25], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "However , novel compounds such as the aurora kinase inhibitors , eg , danusertib ( formerly PHA-739358 ) , homoharringtonine , and ponatinib , successfully target the T315I mutation , and clinical trials are currently being carried out , with the first results looking very promising , as reviewed elsewhere .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [131, 140], "tok_span": [37, 41]}, {"name": "T315I", "ent_type": "variant", "char_span": [167, 172], "tok_span": [45, 49]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [167, 172], "obj_char_span": [131, 140], "rel_type": "response", "sbj_tok_span": [45, 49], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "T315I is a unique mutation making the CML patient irresponsive to all available TKIs but ponatinib and allografting.–", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [89, 98], "tok_span": [22, 26]}, {"name": "T315I", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [0, 5], "obj_char_span": [89, 98], "rel_type": "response", "sbj_tok_span": [0, 4], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "The clinically most notorious Abl1 mutant is T315I , which is resistant to all KIs except ponatinib ( recently approved in the US and EU ) and rebastinib ( currently studied in clinical trials ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [24, 28]}, {"name": "T315I", "ent_type": "variant", "char_span": [45, 50], "tok_span": [11, 15]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [45, 50], "obj_char_span": [90, 99], "rel_type": "response", "sbj_tok_span": [11, 15], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Imatinib ( Gleevec® ) was the first compound used in therapy , but mutations on TK1 domain , known also ATP binding pocket , ( V654A , T670I gatekeeper mutations of c-kit ) led to reduced effectiveness or ineffectiveness of this treatment .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "( V654A", "ent_type": "variant", "char_span": [125, 132], "tok_span": [29, 34]}, {"name": "Gleevec®", "ent_type": "drug", "char_span": [11, 19], "tok_span": [3, 7]}, {"name": ", T670I", "ent_type": "variant", "char_span": [133, 140], "tok_span": [34, 39]}], "relation_list": [{"subject": "( V654A", "object": "Imatinib", "sbj_char_span": [125, 132], "obj_char_span": [0, 8], "rel_type": "resistance", "sbj_tok_span": [29, 34], "obj_tok_span": [0, 2]}, {"subject": "( V654A", "object": "Gleevec®", "sbj_char_span": [125, 132], "obj_char_span": [11, 19], "rel_type": "resistance", "sbj_tok_span": [29, 34], "obj_tok_span": [3, 7]}, {"subject": ", T670I", "object": "Imatinib", "sbj_char_span": [133, 140], "obj_char_span": [0, 8], "rel_type": "resistance", "sbj_tok_span": [34, 39], "obj_tok_span": [0, 2]}, {"subject": ", T670I", "object": "Gleevec®", "sbj_char_span": [133, 140], "obj_char_span": [11, 19], "rel_type": "resistance", "sbj_tok_span": [34, 39], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "More recently , Ashida et al. investigated six acral melanoma cell lines , indicating that sunitinib was better sensitive to c-kit D820Y mutant cells with the secondary resistance to imatinib while the wild type cells did not change .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [183, 191], "tok_span": [39, 41]}, {"name": "D820Y", "ent_type": "variant", "char_span": [131, 136], "tok_span": [28, 32]}], "relation_list": [{"subject": "D820Y", "object": "imatinib", "sbj_char_span": [131, 136], "obj_char_span": [183, 191], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [39, 41]}], "umls_entity_list": []}, {"text": "Computed tomography ( CT ) scans of a NSCLC patient ( case # 5 , Table ) with two sensitive EGFR mutations ( L858R in exon 21 and G873E in exon 21 ) and a PIK3CA mutation ( E542K in exon 9 ) a ) CT at baseline , and b ) CT taken 5 months after treatment initiation with erlotinib/cetuximab/bevacizumab demonstrating a PR ( -55 % ) .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [270, 301], "tok_span": [73, 85]}, {"name": "E542K", "ent_type": "variant", "char_span": [173, 178], "tok_span": [48, 52]}], "relation_list": [{"subject": "E542K", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [173, 178], "obj_char_span": [270, 301], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [73, 85]}], "umls_entity_list": []}, {"text": "Of the two EGFR mutation positive patients with a simultaneous PIK3CA mutation , one patient ( case # 5 , Table ) with an E542K mutation in exon 9 of the PIK3CA gene in addition to two sensitive EGFR mutations ( L858R and G873E in exon 21 ) , achieved a PR ( -55 % ) for 9+ months on erlotinib/cetuximab/bevacizumab .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [284, 315], "tok_span": [77, 89]}, {"name": "E542K", "ent_type": "variant", "char_span": [122, 127], "tok_span": [27, 31]}], "relation_list": [{"subject": "E542K", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [122, 127], "obj_char_span": [284, 315], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [77, 89]}], "umls_entity_list": []}, {"text": "A recently published experience found a correlation between BRAF V600E activating mutation , mutually exclusive with KRAS ones , and resistance to the treatment with cetuximab and panitumumab administered alone or in combination with chemotherapy ( ) .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [166, 175], "tok_span": [28, 32]}, {"name": "V600E", "ent_type": "variant", "char_span": [65, 70], "tok_span": [9, 12]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [65, 70], "obj_char_span": [166, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 12], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Doody and colleagues studied the activity of cetuximab with NSCLC lines bearing both wild-type EGFR and those with activating mutations in the intracellular kinase domain : not only those known to confer sensitivity to gefitinib and erlotinib ( L858R and delL747-T753insS ) but also the TKI-resistant mutation T790M .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [45, 54], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [310, 315], "tok_span": [74, 78]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [310, 315], "obj_char_span": [45, 54], "rel_type": "response", "sbj_tok_span": [74, 78], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "The identification of the mutations located in codons 12 and 13 , for example , 90 % of KRAS mutations in accordance with European KRAS Quality Assurance Program , is also a point to focus , according to recent studies suggesting that patients with KRAS G13D mutated tumors could benefits of cetuximab therapy .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [292, 301], "tok_span": [57, 61]}, {"name": "G13D", "ent_type": "variant", "char_span": [254, 258], "tok_span": [49, 52]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [254, 258], "obj_char_span": [292, 301], "rel_type": "resistance or non-response", "sbj_tok_span": [49, 52], "obj_tok_span": [57, 61]}], "umls_entity_list": []}]